腺相关病毒介导的基因治疗在肿瘤中的研究进展

基础医学与临床 ›› 2021, Vol. 41 ›› Issue (4): 573-577.

腺相关病毒介导的基因治疗在肿瘤中的研究进展

杨小娟^1,2, 李振昊³, 苟元凤^1,2, 火夏琴^1,2, 裴亚萍^1,2, 李娜^1,2, 刘会玲^2*

1.甘肃中医药大学临床医学院, 甘肃兰州 730700;
2.甘肃省人民医院妇产科, 甘肃兰州 730700;
3.甘肃省人民医院临床研究与转化医学研究所, 甘肃兰州 730700

收稿日期:2020-04-11 修回日期:2020-07-27 出版日期:2021-04-05 发布日期:2021-04-05
通讯作者: ^*Liuhuiling75@163.com
基金资助:
国家自然科学基金(81560426);甘肃省人民医院院内科研基金(20GSSY1-4)

Advances in adeno-associated virus mediated gene therapy in tumors

YANG Xiao-juan^1,2, LI Zhen-hao³, GOU Yuan-feng^1,2, HUO Xia-qin^1,2, PEI Ya-ping^1,2, LI Na^1,2, LIU Hui-ling^2*

1. School of Clinical Medicine, Gansu University of Traditional Chinese Medicine, Lanzhou 730700;
2. Department of Gynaecology and Obstetrics, Gansu Provincial People's Hospital, Lanzhou 730700;
3. Institute of Clinical Research and Translational Medicine, Gansu Provincial People's Hospital, Lanzhou 730700, China

Received:2020-04-11 Revised:2020-07-27 Online:2021-04-05 Published:2021-04-05
Contact: ^*Liuhuiling75@163.com

摘要/Abstract

摘要： 腺相关病毒(AAV)是一种有复制缺陷的非致病人类细小病毒。AAV载体利用病毒对细胞的感染能力,将携带的外源基因转移到细胞中,对长期基因矫正和基因治疗具有一定的优越性,因此成为传导目的基因的理想载体。因其宿主广泛、安全性强、介导外源基因持续表达等优点,现已用于多种肿瘤性疾病的基因治疗研究中。

关键词: AAV, 载体, 基因治疗, 肿瘤

Abstract: Adeno-associated virus (AAV) is a human parvovirus with defects and no disease.AAV vector, as an ideal carrier for the transduction of target genes, has certain advantages in long-term gene correction and gene therapy by transferring foreign bases into cells by using the virus's capacity to infect cells.Due to its advantages of extensive host, strong safety and continuous expression of foreign genes, AAV has been used in gene therapy for a variety of tumor.

Key words: AAV, vectors, gene therapy, tumor

中图分类号:

杨小娟, 李振昊, 苟元凤, 火夏琴, 裴亚萍, 李娜, 刘会玲. 腺相关病毒介导的基因治疗在肿瘤中的研究进展[J]. 基础医学与临床, 2021, 41(4): 573-577.

YANG Xiao-juan, LI Zhen-hao, GOU Yuan-feng, HUO Xia-qin, PEI Ya-ping, LI Na, LIU Hui-ling. Advances in adeno-associated virus mediated gene therapy in tumors[J]. Basic & Clinical Medicine, 2021, 41(4): 573-577.

参考文献

[1] Santiago-Ortiz JL, Schaffer DV. Adeno-associated virus vectors in cancer gene therapy[J]. J Control Release,2016,240: 287-301.
[2] Büning H, Srivastava A. Capsid modifications for targeting and improving the efficacy of AAV vectors[J]. Mol Ther Methods Clin Dev, 2019, 12:248-265.
[3] Luo J, Luo Y, Sun J, et al. Adeno-associated virus-mediated cancer gene therapy: current status[J]. Cancer Lett, 2015, 356: 347-561.
[4] Mak K,Indu G,Peter W,et al. The adeno-associated virus-a safe and promising vehicle for liverspecific gene therapy of inherited and non-inherited disorders[J]. Curr Gene Ther, 2017, 17: 4-16.
[5] Julien L, Chassagne J, Peccate C, et al. RFX1 and RFX3 transcription factors interact with the dsequence of adeno-associated virus inverted terminal repeat and regulate aav transduction[J]. Sci Rep, 2018. doi: 10.1038/s41598-017-18604-3.
[6] Sato N, Saga Y, Uchibori R, et al. Eradication of cervical cancer in vivo by an aav vector that encodes shRNA targeting human papillomavirus type 16E6/E7[J]. Int J Oncol,2018, 52: 687-696.
[7] Louboutin JP, Wang L, Wilson M, et al.Gene transfer into skeletal muscle using novel aav serotypes[J]. J Gene Med,2005,7:442-451.
[8] Zhu J, Liu JQ, Shi M, et al. IL-27 gene therapy induces depletion of tregs and enhances the efficacy of cancer immunotherapy[J]. JCI Insight,2018,3. doi:10.1172/jci.insight.98745.
[9] Doherty FC, Schaack JB, Sladek M. et al. Comparison of the efficacy of four viral vectors for transducing hypothalamic magnocellular neurosecretory neurons in the rat supraoptic nucleus[J]. J Neurosci Methods, 2011, 197: 238-248.
[10] Yin L, Keeler GD, Zhang Y, et al. AAV3-miRNA vectors for growth suppression of human hepatocellular carcinoma cells in vitro and human liver tumors in a murine xenograft model in vivo[J]. Gene Ther, 2020. doi:10.1038/s41434-020-0140-1.
[11] Shen S, Troupes AN, Pulicherla N, et al. Multiple roles for sialylated glycans in determining the cardiopulmonary tropism of adeno-associated virus 4[J]. J Virol, 2013, 87: 13206-13213.
[12] Van LP, Domm JM, Rindler TN, et al. A novel triple-mutant AAV6 capsid induces rapid and potent transgene expression in the muscle and respiratory tract of mice[J]. Mol Ther Methods Clin Dev, 2018, 9: 323-329.
[13] Enomoto M, Hirai T, Kaburagi H, et al. Efficient gene suppression in dorsal root ganglia and spinal cord using adeno-associated virus vectors encoding short-hairpin RNA[J]. Methods Mol Biol, 2016, 1364: 277-290.
[14] Mori S, Takeuchi T, Enomoto Y, et al. Tissue distri-bution of cynomolgus adeno-associated viruses AAV10, AAV11, and aav cy7 in naturally infected monkeys[J]. Arch Virol, 2008, 153: 375-380.
[15] Cao Y. Off-tumor target—beneficial site for antiangiogenic cancer therapy?[J]. Nat Rev Clin Oncol,2010,7: 604-608.
[16] Nagy J, Chang SH, Shih SC, et al. Heterogeneity of the tumor vasculature[J]. Semin Thromb Hemost,2010,3:321-331.
[17] He SS,Shi HS,Yin T,et al. AAV-mediated gene transfer of human pigment epithelium-derived factor inhibits lewis lung carcinoma growth in mice[J]. Oncol Rep,2012, 27:1142-1148.
[18] Mao Y, Pei N, Chen X, et al. A 1-7 overexpression mediated by a capsid-optimized aav8 vector leads to significant growth inhibition of hepatocellular carcinoma[J]. Int J Biol Sci,2018,14:57-68.
[19] Hossain JA, Riecken K, Miletic H, et al. Cancer suicide gene therapy with tk.007[J]. Methods Mol Biol, 2019,1895: 11-26.
[20] Zeng ZJ, Sheng SG, Xue WW,et al. The cell death and DNA damages caused by the tet-on regulating hsv-tk/gcv suicide gene system in mcf-7 cells[J]. Biomed Pharmacother,2014,68: 887-892.
[21] Chen J, Liu X, Chen X, et al. Real-time monitoring of miRNA function in pancreatic cell lines using recombinant aav-based miRNA asensors[J]. PLoS One, 2013, 8: e66315. doi:10.1371/journal.pone.0066315.
[22] Ruan Q, Xi L, Boye SL, et al. Development of an anti-angiogenic therapeutic model combining scaav2-delivered siRNAs and noninvasive photoacoustic imaging of tumor vasculature development[J]. Cancer Lett,2013,332:120-129.
[23] Nieto K, Kern A, Leuchs B, et al. Combined prophy-lactic and therapeutic intranasal vaccination against human papillomavirus type-16 using different adeno-associated virus serotype vectors[J]. Antivir Ther Lond,2009,14:1125-1137.
[24] Chen YL, Chang MC, Chiang YC, et al. Immuno-modulators enhance antigen-specific immunity and anti-tumor effects of mesothelin-specific chimeric DNA vaccine through promoting dc maturation[J]. Cancer Lett, 2018, 425: 152-163.
[25] Hensel JA, Khattar V, Ashton R, et al. Recombinant aav-cea tumor vaccine in combination with an immune adjuvant breaks tolerance and provides Protective Immunity[J]. Mol Ther Oncolytics,2019,12: 41-48.